• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Hyloris announces plans to develop an intranasal TRPV1 agonist for the treatment of idiopathic rhinitis

Belgium-based Hyloris Pharmaceuticals announced that it has added an intranasal TRPV1 agonist (HY-083) for the treatment of idiopathic rhinitis to its pipeline. TRPV1 (transient receptor potential cation channel subfamily V member 1) is overexpressed in the nasal mucosa in idiopathic rhinitis. According to the company, "Hyloris’ treatment approach is to activate and … [Read more...] about Hyloris announces plans to develop an intranasal TRPV1 agonist for the treatment of idiopathic rhinitis

Kindeva Drug Delivery to merge with Meridian Medical Technologies

CDMO Kindeva Drug Delivery, which specializes in inhalation, intradermal, and transdermal drug delivery, has announced that it will merge with fellow Altaris Capital Partners company Meridian Medical Technologies, which specializes in autoinjectors. Altaris acquired Kindeva (formerly 3M Drug Delivery Systems) from 3M in 2020 and acquired Meridian from Pfizer in 2021. … [Read more...] about Kindeva Drug Delivery to merge with Meridian Medical Technologies

Relief Therapeutics gets exclusive rights to aviptadil in settlement with NRx Pharmaceuticals

Relief Therapeutics and NRx Pharmaceuticals (formerly NeuroRx) said that they have settled litigation that originated with a dispute over payment for a clinical trial of nebulized aviptadil (RLF-100) for the treatment of COVID-19. According to the companies, Relief will take possession of all NRx assets related to aviptadil, "including its regulatory filings, patent … [Read more...] about Relief Therapeutics gets exclusive rights to aviptadil in settlement with NRx Pharmaceuticals

Phase 3 trial of Satsuma’s STS101 DHE nasal powder for migraine fails to meet primary endpoints

Following the failure of the Phase 3 SUMMIT trial of its STS101 dihydroergotamine (DHE) nasal powder for the treatment of migraine to meet the study's primary endpoints, Satsuma Pharmaceuticals says that the company will not invest in commercialization of the product. In September 2020, the company announced that the Phase 3 EMERGE trial of STS101 failed to meet its … [Read more...] about Phase 3 trial of Satsuma’s STS101 DHE nasal powder for migraine fails to meet primary endpoints

Indivior to acquire Opiant Pharmaceuticals

Narcan naloxone nasal spray developer Opiant Pharmaceuticals has agreed to be acquired by Indivior for $20 per share at closing, plus up to $8 contingent value rights (CVRs) per share based on achievement of revenue goals for Opiant's OPNT003 intranasal nalmefene over a 7-year period, the company said. Both boards of directors have approved the deal, and the … [Read more...] about Indivior to acquire Opiant Pharmaceuticals

Court finds Symbicort patent invalid in win for Viatris and Kindeva

According to Viatris, the US District Court for the Northern District of West Virginia has determined that US Patent No. 10,166,247, which covers AstraZeneca's Symbicort budesonide / formoterol MDI, is invalid. In March 2021, the same court upheld claims in three other patents protecting Symbicort. An appeals court reversed the March 2021 decision in December 2021 and … [Read more...] about Court finds Symbicort patent invalid in win for Viatris and Kindeva

Viatris to acquire Oyster Point Pharma

Tyrvaya varenicline nasal spray maker Oyster Point Pharma announced that its board of directors has approved the company's plans to be acquired by Viatris for $11 per share at closing plus up to $2 per share if Oyster Point achieves certain performance goals for 2022. The FDA approved Tyrvaya for the treatment of dry eye disease in October 2021. Oyster Point is also … [Read more...] about Viatris to acquire Oyster Point Pharma

TFF Pharmaceuticals developing dry powder vaccines delivered via an Aptar Pharma nasal device

TFF Pharmaceuticals announced that it has been working with Aptar Pharma on a project to develop dry powder vaccines based on TFF's thin film freezing particle manufacturing platform and Aptar Pharma’s Unidose (UDS) nasal powder delivery device. According to the company, Aptar Pharma presented data from the project at the recent Vaccines Summit 2022 and will present … [Read more...] about TFF Pharmaceuticals developing dry powder vaccines delivered via an Aptar Pharma nasal device

Birmingham Biotech launches NoriZite gelling nasal spray for the prevention of viral infections in the UK

Birmingham Biotech has announced the launch of NoriZite carageenan/gellan gum nasal spray for the prevention of viral infections in the UK. The formulation, which is designed to physically block viruses in the nasal cavity, was developed at the University of Birmingham's Healthcare Technologies Institute, and Birmingham Biotech acquired the rights to the nasal spray … [Read more...] about Birmingham Biotech launches NoriZite gelling nasal spray for the prevention of viral infections in the UK

United Therapeutics request for review of PTAB decision on Tyvaso patent is denied

According to Liquidia, the US Patent and Trademark Office's Precedential Opinion Panel (POP) will not review a July 2022 Patent Trial and Appeals Board (PTAB) decision which determined that none of the claims in US Patent No. 10,716,793, which covers United Therapeutics' Tyvaso inhaled treprostinil, are valid. United Therapeutics had requested both a POP review of the … [Read more...] about United Therapeutics request for review of PTAB decision on Tyvaso patent is denied

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews